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INFECTION – Clinical Outcomes Studies
PIN1
COST AND QUALITY OF LIFE ISSUES ASSOCIATED WITH PROTEASE 
INHIBITOR-BASED COMBINATION THERAPY TO TREAT HEPATITIS C
Carter J1, Gao X1, Stephens JM1, Rustgi V2, Haider S3
1Pharmerit North America, LLC, Bethesda, MD, USA; 2Georgetown University Medical 
Center, Fairfax, VA, USA; 3Pﬁ zer Inc., New London, CT, USA
OBJECTIVES: To systematically analyze the literature to assess the economic and 
health-related quality of life (HRQoL) impact of adverse events (AEs) related to the 
addition of protease inhibitors (PI) to standard of care (SOC) for the treatment of 
hepatitis C (HCV). METHODS: A literature search (2000-Present) was conducted to 
identify and analyze clinical trials for PI triple therapy (PITT = PI + SOC) and SOC 
(PEGIFN/RBV for 48 weeks). HRQoL and safety data were synthesized by study 
design, sample characteristics, and AEs. Economic and resource use data were synthe-
sized in an economic analysis of AEs in PITT vs. SOC. Costs (2009) were derived 
from published literature. RESULTS: Twenty-three SOC and 7 PITT trials were identi-
ﬁ ed. Statistically signiﬁ cant (p = or <0.05) changes from baseline were most often seen 
in trials of SOC in the following domains: vitality, depression, physical limitations, 
and fatigue. The following 4 PITT-related AEs could be linked to HRQoL domains: 
anemia and depression were linked to fatigue and vitality, and headache and rash were 
linked to physical limitations. In terms of economic impacts, the costs to manage a 
PITT-related episode of anemia, depression, diarrhea, and rash were $4825, $2837, 
$566, and $633, respectively. The average AE cost in PITT ranged from $1732 to 
$3578. Corresponding costs in SOC ranged from $1608 to $2229. The treatment 
costs of PITT-related AEs were 30% (range 8–60%) higher than the cost of treating 
SOC-related AEs. CONCLUSIONS: The costs to manage PITT-related AEs appear 
higher than the costs of SOC-related AEs. Since PITT is associated with higher AE 
rates, it can also be expected to result in worse HRQoL. Gaps in symptom burden 
assessment with existing instruments also exist. Future studies should incorporate the 
economic burden of AEs and the appropriate use of HCV-validated instruments to 
capture potential HRQoL differences among treatment strategies.
PIN2
ESTIMATED IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ON LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND 
LIFETIME COSTS IN CHRONIC HEPATITIS C (CHC) PATIENTS
Cure S1, Bianic F1, Cawston H1, Dartois L1, Zhang H2
1i3 Innovus, Uxbridge, Middlesex, UK; 2Johnson & Johnson Pharmaceutical Services, LLC, 
Raritan, NJ, USA
OBJECTIVES: The World Health Organization considers hepatitis C a global burden. 
CHC is a curable disease since patients achieving SVR can remain virus-free. We 
evaluated CHC treatment for efﬁ cacy (SVR) and long-term effects on reduction of 
disease progression to advanced stages, improvement in quality of life, and reduction 
of health care costs. The objective was to estimate the burden of disease and impact 
of SVR in CHC patients on lifetime life-years (LY), QALYs and costs using a Markov 
model and published literature. METHODS: A systematic literature review identiﬁ ed 
publications reporting the cost-effectiveness of antiviral therapies in CHC (November 
2009). PubMed, CRD and Health Technology Assessment reports were searched. We 
selected all cost-effectiveness (CE) studies with a similar Markov structure including 
eight health states (SVR, mild/moderate CHC, compensated and decompensated cir-
rhosis, hepatocellular carcinoma [HCC], liver transplant and death). CE inputs were 
used to populate a Markov model to estimate average lifetime beneﬁ ts and costs 
associated with SVR and non-SVR. Age of entry in the model was 40 years. Costs 
were updated to 2008 Great Britain Pounds (GBP). Discount rates for costs and 
outcomes were 3.5%. RESULTS: 893 unique references were retrieved and 14 articles 
met the inclusion criteria. Compared to non-SVR patients, the SVR group was con-
sistently associated with more LYs (18.33, range [18.05;18.53] versus 17.49, range 
[16.17;18.51]) and more QALYs (15.81, range [14.8;17.87] versus 13.25, range 
[11.9;14.03]). Lifetime costs associated with non-SVR patients (£20,406, range 
[£7,186;£41,383]) were also consistently higher than with SVR patients (£11,156, 
range [£5,449;£14,582]). CONCLUSIONS: Using this model, the SVR group was 
consistently associated with longer life expectancy and more QALYs. Complications 
avoided by reaching SVR were associated with reduced lifetime CHC costs. It will be 
important to account for these correlations with lifetime beneﬁ ts and costs when the 
values of an antiviral treatment in CHC are evaluated.
PIN3
PRESCRIBER INFLUENCE ON THE PREVALENCE OF POTENTIAL 
ANTIRETROVIRAL DRUG-DRUG INTERACTIONS ON PRESCRIPTIONS 
IN SOUTH AFRICA
Katende-Kyenda NL1, Lubbe MS2, Serfontein JHP2, Truter I3
1Walter Sisulu University, Mthatha, Eastern Cape, South Africa; 2North-West University, 
Potchefstroom, South Africa; 3Nelson Mandela Metropolitan University (NMMU), Port 
Elizabeth, Eastern Cape, South Africa
OBJECTIVES: The purpose was to determine the prevalence of potential drug-drug 
interactions (DDIs) between antiretroviral (ARV) drugs on prescriptions prescribed by 
general practitioners and specialists in South Africa and the evaluation of the pre-
scribed daily doses (PDDs) of the interacting drugs. METHODS: A quantitative, 
retrospective drug utilization study was performed on 49,995, 81,096 and 88988 ARV 
prescriptions claimed through a South African pharmacy beneﬁ t management 
company during 2005 to 2007. Potential DDIs between ARVs were identiﬁ ed and 
classiﬁ ed according to a clinical signiﬁ cance rating. The clinical signiﬁ cance ratings of 
potential DDIs are described in three degrees of severity, identiﬁ ed as major, moderate 
and minor as described by Tatro. (RSA Rand(R)/$US = 6.8595 on 31 December 2007). 
RESULTS: Antiretroviral drugs represented 0.91% of all drugs (N = 59 971 226) 
claimed during the three years at a total cost of N = R 5 758 783 544 (1.92%). The 
average cost of antiretroviral prescriptions decreased with 4.19% from 2005 (R524.40 
± R178.79) to 2007 (R502.41 ± R161.19). ARV prescriptions prescribed by general 
practitioners with potential DDIs and PDDs not according to recommended ARV 
dosing increased dramatically from 12.33% in 2005 to 24.26% in 2007. Those pre-
scribed by specialists increased from 15.46% in 2005 to 35.30% in 2006 and 
decreased to 33.16% in 2007. The highest percentage of ARV prescriptions with 
potential DDIs and PDDs not according to the recommended ARV dosing guidelines 
were identiﬁ ed in ARV regimens between lopinavir/ritonavir at PDD 1066.4 mg/264 mg 
and efavirenz at PDD 600 mg prescribed to patients 19 to 45 years. These regimens 
were mostly prescribed by general practitioners as compared to specialists. CONCLU-
SIONS: There is need for more education of prescribers to be aware of the potential 
medication-prescribing errors associated with highly active antiretroviral therapy 
which could lead to treatment failures, development of resistance and DDIs.
PIN4
IMPACT OF MMRV MASS VACCINATION WITH OR WITHOUT A 
CATCH UP PROGRAM ON THE INCIDENCE OF VARICELLA 
COMPLICATIONS IN FRANCE
Ouwens M1, Littlewood K1, Sauboin C2, Tehard B3, Alain S4, Denis F5, Boelle PY6
1Mapi Values, Houten, The Netherlands; 2GlaxoSmithKline Biologicals, Rixensart, Belgium; 
3Laboratoire GlaxoSmithKline, Marly le Roi, France; 4French National Cytomegalovirus 
Reference Center, Limoges, France; 5CHU Dupuytren, Limoges, France; 6Université Pierre et 
Marie Curie, Paris, France
OBJECTIVES: Varicella complications place a large burden on health care resources, 
however, varicella is preventable by mass vaccination with MMRV. The impact on 
complications of three MMRV programs were explored. METHODS: An age-struc-
tured dynamic model compared natural and breakthrough varicella following mass 
vaccination, to current cases. Age-speciﬁ c complication rates (neurologic, cutaneous, 
pulmonary, other) were applied per case. MMRV replaced 80% of MMR over 1 year 
(basecase) compared to 100% of MMR with a catch-up in 11–13 year-olds (‘catch 
up’). In an ‘optimal’ scenario, MMR coverage increased from 90% to 95% (1st dose) 
and 60% to 90% (2nd dose), MMRV replaced 100% MMR within 1 year with a 
catch-up in 10 year-olds. RESULTS: MMRV decreased varicella incidence and caused 
an age shift, however, many post-vaccination cases were breakthrough cases, believed 
to be milder and require less resource use. Prior to MMRV: highest varicella incidence 
(per million-person-years of total population) was among 1–4 year-olds (7,482 cases), 
with 355 complications (age-speciﬁ c complication rate: 4.75%). Basecase: highest 
incidence among 10–14 year-olds (907 natural, 633 breakthrough), with 54 complica-
tions (age-speciﬁ c rate: 3.53%); 85% lower versus 1–4 year-olds. ‘Catch-up’: highest 
incidence among 15–24 year-olds (161 natural, 398 breakthrough), with 49 complica-
tions (age-speciﬁ c rate: 8.82%); 86% lower versus 1–4 year-olds. ‘Optimal’: highest 
incidence among 15–24 year-olds (22 natural, 80 breakthrough), with 9 complica-
tions; 97.5% lower versus 1–4 year-olds. Assuming breakthrough cases have 10% of 
complications of natural cases, the incidence in the basecase, catch-up and optimal 
scenarios becomes: 34, 18 and 3 complications respectively. Despite greater risks of 
complications in older age groups, the reduction in varicella cases signiﬁ cantly reduced 
the incidence of complications. The ICER remained below c16,000 (direct costs). 
CONCLUSIONS: Mass varicella vaccination is predicted to signiﬁ cantly reduce vari-
cella and complication cases. As many vaccine era cases will be breakthrough; burden 
to patients and health care systems may be reduced further.
PIN5
HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH 
AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING 
EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE
Toussi M, Pertus D, Antonio M, Robain M
CSD, Boulogne, Billancourt, France
OBJECTIVES: In the context of an epidemic, public health authorities need to have 
real time information of the disease propagation to make appropriate and timely 
decisions. We present our experience in using centralized electronic patient records in 
the early detection and follow-up of Flu A/H1N1 epidemic in France. METHODS: 
We used Longitudinal Patient Data (LPD), which is a dynamic centralized database 
of more than 1.3 million anonymous patient records uploaded regularly by a network 
of 1300 representative general practitioners and pediatricians in France. The trends 
of seasonal inﬂ uenza, Flu A/H1N1 and ﬂ u-like syndrome diagnoses are traced and 
compared with the reports published by Sentinel Network, a group of trained physi-
cians set up by public authorities. RESULTS: The trends of seasonal inﬂ uenza, Flu A/
H1N1, and ﬂ u-like syndrome obtained from LPD database show a very close similarity 
with those published by Sentinel Network (Pearson’s correlation coefﬁ cient = 0.97). 
The seasonal pattern of the incidence of inﬂ uenza and ﬂ u-like syndrome were less 
similar between 2009 and 2008 (Pearson’s correlation coefﬁ cient = 0.60), which can 
be explained by an over declaration of all kinds of ﬂ u by the doctors during the second 
half of 2009. There was also a close similarity between seasonal Flu, approved Flu A/
H1N1, and ﬂ u-like syndrome trends with a peak incidence in late November 2009. 
CONCLUSIONS: The LPD data matched very closely the results published by the 
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ofﬁ cial Sentinel Network. The advantage of the LPD data is that its trends are available 
almost in real time, whereas the active reporting of the doctors of Sentinel Network 
is done on a weekly basis. However, the LPD trends lack of geographical precision 
because of the censorship of the post codes of patient during the de-identiﬁ cation 
process. We recommend a combined use of LPD and Sentinel Networks in the follow 
up of future epidemics.
PIN6
A MULTIVARIATE MODEL: PREDICTORS OF DISEASE PROGRESSION IN 
HIV/AIDS PATIENTS IN WESTERN NEW YORK
Voltz C1, Castleman C2, Purdy C2, Magar R3
1Aids Community Services of Western New York, Buffalo, NY, USA; 2AHRM Inc., Buffalo, 
NY, USA; 3AHRM Inc., Raleigh, NC, USA
OBJECTIVES: The medical care of HIV/AIDS patients is becoming increasingly 
complex involving a host of issues including medication management, co-infections, 
cardiovascular risk factors and patient characteristics. This analysis used a set of 
patient characteristics and treatment patterns to explore potential predictors of HIV 
progression. METHODS: Aids Community Services of Western New York provides 
primary medical care services to approximately 600 HIV/AIDS patients yearly in 
WNY. A total of 1128 patients, receiving care from August 2006 through June 2010 
were included in the analysis. The patient characteristics, health indicators, medication 
information and risk factors were used as potential predictors of disease progression. 
Disease progression was measured by the surrogate endpoints of CD4 counts and 
CD4/CD8 ratio values. a mixed model with a repeated structure was ﬁ t to the data 
set (with a signiﬁ cance level of 0.05). RESULTS: The patient population was com-
prised of 757 men and 371 women; the average age of the population was 44 years. 
The population sampled was predominantly Caucasian, African American and His-
panic (39%, 39%, and 19%). The most common HIV medications administered to 
these patients were ritonavir, a tanofovir/emtricitabine combination, atazanavir and 
a lopinavir/ritonavir combination. The most common risk factors in this population 
were male with male sex, heterosexual sex and IV Drug use (27%, 15%, and 9%). 
For the multivariate model utilizing the CD4 counts as the outcome variable, only 
medications and cardiovascular risk factors were signiﬁ cant predictors. For the mul-
tivariate model utilizing the CD4/CD8 ratio as the outcome variable, only the HIV 
risk factors and medications were signiﬁ cant predictors. Both models achieved global 
statistical signiﬁ cance. CONCLUSIONS: The management of HIV/AIDS is an increas-
ingly complex problem which requires constant advances in both research and prac-
tice. This exploratory analysis was able to identify signiﬁ cant relationships between 
patient characteristics, treatment patterns and measures of disease progression. 
INFECTION – Cost Studies
PIN7
BUDGET IMPACT MODEL FOR CATCH-UP PROGRAM WITH 13 VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN UNDER 5 
YEARS OLD IN THE AUTONOMOUS REGION OF MADRID (RM)
Picazo J1, Gil de Miguel A2, Mendez C3, Guijarro P3, Garcia L3
1University Complutense of Madrid, Madrid, Spain; 2Rey Juan Carlos University, Alcorcon, 
Madrid, Spain; 3Pﬁ zer Spain, Alcobendas, Madrid, Spain
OBJECTIVES: Madrid Health Authorities decided the introduction of Pneumococcal 
Conjugate Vaccine (PCV) as systematic use for infants in November 2006 (3 + 1 
pattern; 2, 4, 6 + 18 months). Recently, a ﬂ awless transition to PCV13 has been 
recommended. This study was aimed to assess the budget impact of an additional 
catch-up vaccination strategy from the age of 19 to 60 months. METHODS: A one-
year budget impact model has been developed stratifying population by age groups 
(19 to 24, 25 to 36, 37 to 48 and 49 to 60 months) and diseases (IPD and Non-IPD). 
Clinical data, PCV13 serotype coverage and disease related costs were based on 
published data. Model was built up under regional health care system perspective and 
assumed 80% of coverage for PCV13. Indirect effect was not considered. All costs 
were expressed in c2010. RESULTS: The model predicts that the implementation of 
a catch-up vaccination program with PCV13 in the RM would be a cost saving 
measure in infant groups from 19 to 36 months due to disease burden reduction caused 
by the 6 PCV13 additional serotypes. Globally, 49.6% of IPD, 58.9% of OMA 
and 47.1% of out-patient pneumonia cases would be prevented in these groups. 
CONCLUSIONS: Based on this health economic evaluation, the inclusion of a catch-
up program with PCV13 in the RM would be an efﬁ cient measure. Model results 
showed that a PCV13 catch-up dose would have a high impact on pneumococcal 
disease prevention, avoiding its related costs.
PIN8
COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) 
WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH 
RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
Omelyanovsky VV, Avksentieva MV, Krysanov I, Ivakhnenko O
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, 
Russia
OBJECTIVES: Combination therapy with pegylated interferon with ribavirin is the 
standard of care for the treatment of chronic hepatitis C infection. This analysis 
compares the cost efﬁ cacy of of combined antiviral therapy with peginterferon 
alfa—2b with ribavirin compared peginterferon alfa—2Ü with ribavirin for treatment 
at patients with a hepatitis C infection counting for 1 patient. METHODS: A decision 
analysis model was constructed from the viewpoint of a managed care organization 
to compare Peg-2b plus RBV (1.5 mcg per kilogram per week plus RBV 1000 mg per 
day) and Peg-2a plus RBV (180 mcg per week plus RBV 1000 mg per day). For 
purposes of this analysis, distribution on genotypes and treatment duration and efﬁ -
cacy data were obtained from the published literature. The positive predictive value 
was calculated for each treatment group for genotype 1, which is determined from 
the values for early virologic response and sustained viral response. Genotype 2 and 
genotype 3 were assumed to be treated for 24 weeks. RESULTS: Antiviral therapy of 
combined antiviral therapy with peginterferon alfa—2b with ribavirin is economically 
more favourable in comparison with therapy in a combination peginterferon alfa—2Ü 
with ribavirin and taking into account efﬁ ciency of treatment the difference indicator 
makes c3293 thousand on 1 patient. CONCLUSIONS: Antiviral therapy of combined 
antiviral therapy with peginterferon alfa—2b with ribavirin is economically more 
favourable in comparison with therapy in a combination peginterferon alfa—2Ü with 
ribavirin and taking into account efﬁ ciency of treatment the difference indicator makes 
c3293 thousand on 1 patient.
PIN9
ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT 
HPV TYPES 6, 11, 16, 18 VACCINE IN JAPAN USING A TRANSMISSION 
DYNAMIC MODEL
Yamabe K1, Abe M1, Singhal PK2, Kamae I3
1Banyu Pharmaceutical Co.,Ltd, Tokyo, Japan; 2Merck & Co., Inc., West Point, PA, USA; 3Keio 
University Graduate School of Health Management, Fujisawa, Japan
BACKGROUND: The quadrivalent (6,11,16,18) HPV vaccine has been approved in 
many countries for prevention of cervical cancer, vulvar/vaginal pre-cancers, and 
genital warts in women age 9 to 26 years. OBJECTIVES: To assess the health and 
economic impact of the quadrivalent (6,11,16,18) HPV vaccine in Japan. METHODS: 
A published mathematical model of the transmission dynamics of HPV infection and 
disease was adapted for Japan. Model inputs were used from Japan or the Asia/Paciﬁ c 
region when available; otherwise, the default values in the original model were used. 
Maintaining current cervical cancer screening practices in Japan, we evaluated two 
strategies: routine vaccination of females by age 12 (S1), and S1 combined with a 
temporary (5 years) female catch-up program for age 12–24 years (S2). The vaccine 
coverage rates were 80% for the routine and 50% for the catch-up vaccination pro-
grams. RESULTS: The most effective strategy was S2. Using this strategy over 100 
years in the population of Japan, the estimated cumulative percent reduction in inci-
dent HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical 
intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases was 90% 
(2,113,723 cases), 86% (2,082,637 cases), 72% (263,406 cases), 71% (1,328,366 
cases), and 58% (323,145 cases), respectively. The cost-effectiveness ratios were US$ 
12,434 (weekly dominated), and US$ 12,058 per quality-adjusted life-years (QALY) 
gained for S1 and S2 compared with no vaccination, respectively. CONCLUSIONS: 
In Japan, vaccination of females age 12–24 years with a quadrivalent (6,11,16,18) 
HPV vaccine can reduce the incidence of cervical cancer, CIN, and genital warts at a 
cost per QALY ratio within the range typically regarded as cost-effective.
PIN10
COST VERSUS DRG REVENUE IMPLICATIONS OF TREATING A 
PATIENT WITH VENTILATOR-ASSOCIATED PNEUMONIA (VAP) WITH 
DORIPENEM VERSUS IMIPENEM IN GERMANY
De Cock E1, Gast C2, Berndt K3, Kubitz N3
1United BioSource Corporation, Barcelona, Spain; 2Private Consultant, Seattle, WA, USA; 
3Janssen-Cilag GmbH, Neuss, Germany
OBJECTIVES: A Phase III study of doripenem versus imipenem in VAP (DORI-10) 
has shown a statistically signiﬁ cant reduction in length of stay (LOS) and mechanical 
ventilation (MV) duration with doripenem. This study estimated expected hospital 
cost versus G-DRG payment for a patient treated with doripenem versus imipenem. 
METHODS: From both DORI-10 trial arms, and for nine categories of post-random-
ization MV duration, we obtained percentages of patients per group and median LOS 
by type of ward (ICU with vs. w/out MV, general ward). One clinical expert provided 
ICD and OPS codes for four likely patient proﬁ les, and another expert on intensive 
care severity (TISS/SAPS). Using the Muenster Webgrouper, we determined G-DRG 
weights when simultaneously varying MV duration and intensive care severity (8–890 
code). Per treatment arm and for each MV subgroup, the appropriate G-DRG weight 
was selected based on the selected proﬁ le, total MV duration, 8–980 code, and total 
LOS. Using the distribution of patients by category, a weighted G-DRG was calculated 
for each arm, and G-DRG weight was multiplied by the 2010 base value (c2936) to 
yield expected G-DRG payment. Within each arm, we calculated cost per MV category 
(hospital per diem plus antibiotic therapy) as well as a weighted cost. RESULTS: 
Expected cost for a patient receiving doripenem was c30,183 vs. c32,549 for imipe-
nem. Expected revenue reduction ranged from c2084 to c2428 across 4 scenarios. Net 
budget impact of the introduction of doripenem ranged from −c85 to c282, showing 
that revenue reduction may be more than offset by cost reduction. CONCLUSIONS: 
For a patient receiving doripenem instead of imipenem, reduced hospitalization costs 
more than offset reduced G-DRG revenue in a wide range of cases. In addition, less 
time on the ventilator can improve patient outcomes (including quality-of-life), and 
frees up ICU bed-days, allowing more patients to be treated.
